AQEEL KHAN: Open Payments
NPI 1629046735 · BLOOMINGDALE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 21 payments from 9 companies in 2025. Trend: 2023 $578 · 2024 $483 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 1 | $78 |
| Janssen Pharmaceuticals, Inc | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
| Luye Pharma (USA) Ltd. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
Products named: VRAYLAR, ABILIFY MAINTENA, INVEGA SUSTENNA, UZEDY, CAPLYTA, REXULTI, ERZOFRI EXTENDED-RELEASE, Auvelity.
Industry payments across IL — which companies pay providers there.
